NetworkNewsBreaks – Scinai Immunotherapeutics Lt
Post# of 88
(Total Views: 131)
Posted On: 10/30/2023 5:11:42 PM
NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation at BIO-Europe Munich 2023
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, will be attending and participating in BIO-Europe, one of Europe’s premier pharmaceutical industry partnering events. The event is slated for Nov. 6–8, 2023, in Munich, Germany. According to the announcement, Scinai will showcase both its CDMO services, marketed under the brand Scinai Bioservices, and its in-house nanosized VHH antibody-based therapeutics pipeline. In addition, management will be available to meet with potential partners and clients. Scinai offers a state-of-the-art manufacturing facility for biopharmaceutical products as well as biologic drugs process development and scale-up for protein-based drugs; the company also provides analytical method development for QC testing and cGMP manufacturing. In addition, the company’s in-house R&D program specializes in developing, manufacturing and commercializing I&I biological products targeting the treatment of autoimmune and infectious diseases.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, will be attending and participating in BIO-Europe, one of Europe’s premier pharmaceutical industry partnering events. The event is slated for Nov. 6–8, 2023, in Munich, Germany. According to the announcement, Scinai will showcase both its CDMO services, marketed under the brand Scinai Bioservices, and its in-house nanosized VHH antibody-based therapeutics pipeline. In addition, management will be available to meet with potential partners and clients. Scinai offers a state-of-the-art manufacturing facility for biopharmaceutical products as well as biologic drugs process development and scale-up for protein-based drugs; the company also provides analytical method development for QC testing and cGMP manufacturing. In addition, the company’s in-house R&D program specializes in developing, manufacturing and commercializing I&I biological products targeting the treatment of autoimmune and infectious diseases.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)